Fundraising Fox
Amicus Therapeutics
Cranbury, US · Founded 1997 · Delaware corporation · 3,205 employees on LinkedIn · 5 known investors
Find your way into Amicus Therapeutics
Sign up to see every warm intro you have to Amicus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amicus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Founders & leadership
DQ
Daphne QuimiExecutive
JC
John CrowleyFounder
WD
William D. Baird, IIIExecutive
Board
CA
Craig A. WheelerBoard director
TW
MG
Margaret G. McGlynnBoard director
DJ
Donald J. Hayden, Jr.Board director
SB
Sol BarerBoard director
GS
Glen SblendorioBoard director
RE
Robert EssnerBoard director
MR
Michael RaabBoard director
Investors · 5
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M
How we know: Canaan Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto
How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$234.6M disclosed across 3 rounds · 2016–2023
▶$30MraisedOct 2023 · 2 investors · BiotechnologyRule 506(b)
▶$30MraisedOct 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F CrowleyDirector
- David ClarkExecutive Officer
- Eiry W Roberts, M.D.Director
- Ellen S. RosenbergExecutive Officer
- Margaret G. McGlynnDirector
- Craig A WheelerDirector
- Michael A KellyDirector
- Bradley CampbellExecutive Officer, Director
- Michael G RaabDirector
- Simon HarfordExecutive Officer
- Glenn P SblendorioDirector
- Burke W WhitmanDirector
- Lynn D BleilDirector
- Jeffrey P. Castelli, Ph.D.Executive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$199.9MraisedOct 2021 · 9 investors · BiotechnologyRule 506(b)
▶$199.9MraisedOct 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F. CrowleyExecutive Officer, Director
- Michael A. KellyDirector
- Bradley L. CampbellExecutive Officer, Director
- Michael RaabDirector
- Samantha ProutExecutive Officer
- Margaret G. McGlynnDirector
- Burke W. WhitmanDirector
- Eiry L. RobertsDirector
- Daphne QuimiExecutive Officer
- Craig A. WheelerDirector
- Lynn D. BleilDirector
- Robert EssnerDirector
- Ellen S. RosenbergExecutive Officer
- Glenn P. SblendorioDirector
- David M. ClarkExecutive Officer
- Offering amount
- $199.9M
- Amount sold
- $199.9M
- Minimum investment
- $2.1M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedJul 2016 · 18 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJul 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daphne QuimiExecutive Officer
- Craig A. WheelerDirector
- Ted W. LoveDirector
- John CrowleyExecutive Officer, Director
- William D. Baird, IIIExecutive Officer
- Margaret G. McGlynnDirector
- Donald J. Hayden, Jr.Director
- Sol BarerDirector
- Glen SblendorioDirector
- Robert EssnerDirector
- Michael RaabDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- Sales commissions
- $5K
- Finders' fees
- $5K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Amicus Therapeutics went on to found or lead other companies.
Related companies · 2
AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Amicus Therapeutics.
Frequently asked questions
- What does Amicus Therapeutics do?
- Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
- Who are Amicus Therapeutics's investors?
- Amicus Therapeutics's investors include Avoro Capital Advisors, Canaan Partners, Frazier Life Sciences, New Enterprise Associates (NEA), Prospect Venture Partners.
- How much funding has Amicus Therapeutics raised?
- Amicus Therapeutics has disclosed $234.6M raised across 3 rounds.
- Where is Amicus Therapeutics headquartered?
- Amicus Therapeutics is headquartered in Cranbury, US.